First Time Loading...

G1 Therapeutics Inc
NASDAQ:GTHX

Watchlist Manager
G1 Therapeutics Inc Logo
G1 Therapeutics Inc
NASDAQ:GTHX
Watchlist
Price: 4.44 USD 7.51% Market Closed
Updated: May 3, 2024

G1 Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

G1 Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
G1 Therapeutics Inc
NASDAQ:GTHX
Revenue
$82.5m
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

G1 Therapeutics Inc
Revenue Breakdown

Breakdown by Geography
G1 Therapeutics Inc

Not Available

Breakdown by Segments
G1 Therapeutics Inc

Total Revenue: 82.5m USD
100%
Product Sales, Net: 46.3m USD
56.2%
License Revenue: 36.2m USD
43.8%

See Also

What is G1 Therapeutics Inc's Revenue?
Revenue
82.5m USD

Based on the financial report for Dec 31, 2023, G1 Therapeutics Inc's Revenue amounts to 82.5m USD.

What is G1 Therapeutics Inc's Revenue growth rate?
Revenue CAGR 3Y
22%

Over the last year, the Revenue growth was 61%. The average annual Revenue growth rates for G1 Therapeutics Inc have been 22% over the past three years .